Conventionally, transurethral standard resection (SR) of bladder tumour is performed in a piecemeal manner. Transurethral en bloc resection (EBR) has been described as an alternate surgical technique in bladder tumour resection. By preventing tumour fragmentation and ascertaining complete tumour resection by histological assessment of the EBR specimen, we hypothesized that EBR could reduce disease recurrence as compared to SR.
Conditions: Bladder Cancer
Eligibility Criteria
Inclusion Criteria
- Age ≥ 18 years old with informed consent
Exclusion Criteria
- Bladder tumour base with maximal dimension of \>3cm (Anticipated difficulty in retrieving the specimen en bloc)
- Bladder tumour detected during intravesical BCG therapy (BCG failure warrants more aggressive treatment, i.e. radical cystectomy)
- Histological diagnosis other than NMIBC
- Presence or prior history of upper urinary tract malignancy
- ECOG performance status ≥ 3 (Confined to bed or chair more than 50% of waking hours)
- ASA III or above (Patient with severe systemic disease)
- History of bleeding disorder or use of anti-coagulants
- Pregnancy
- Presence of other active malignancy
- Life expectancy of less than one year
Eligibility criteria are kept as the original English records from ClinicalTrials.gov; actual eligibility is determined by the research team's formal assessment and the informed consent form. Source: ClinicalTrials.gov, updated automatically every two weeks. Last synced: 2026年11月5日.